Market Overview - On August 19, the innovative drug sector experienced a significant surge, with multiple companies including Shenyuan Biological and Xintian Pharmaceutical hitting the daily limit increase [1] Key Events - On August 19, Rongchang Biopharmaceutical announced a licensing agreement for its RC28-E injection with Santen China, receiving an upfront payment of 250 million RMB and potential milestone payments totaling up to 12.45 billion RMB [4] - On August 7, Buchang Pharmaceutical's subsidiary signed an exclusive supply agreement with GOODFELLOW for the registration and sales of Efparepoetinalfa in the Philippines [4] - On July 28, Hengrui Medicine announced a deal with GSK for global exclusive rights to the HRS-9821 project, with an upfront payment of 500 million USD and potential total payments of approximately 12 billion USD [4] - Prior to these announcements, companies like CSPC Pharmaceutical, 3SBio, and China National Pharmaceutical Group also secured significant overseas contracts [5] Institutional Insights - According to data from Toubao, the U.S. pharmaceutical market was valued at 600.3 billion USD in 2022, with innovative drugs accounting for over 70%, approximately 420 billion USD. In contrast, China's pharmaceutical market was valued at 250.8 billion USD, with innovative drugs making up less than 20%, around 50 billion USD [6] - The trend of Chinese pharmaceutical companies collaborating with international giants is increasing, with record-high upfront payments and total transaction amounts. The potential market for domestic innovative drugs could rise from 50 billion USD domestically to over 420 billion USD in the U.S. market alone [6] - Recent catalysts in the innovative drug sector are emerging, with upcoming industry conferences expected to showcase promising data from companies like Diligent Pharma and Fuhong Hanlin [6] - The domestic innovative drug industry is transitioning from a capital-driven model to a profit-driven model, with expectations for performance and valuation recovery opportunities in the sector by 2025 [7]

证券日报网讯 8月7日晚间，步长制药发布公告称，公司第五届董事会第二十八次会议审议通过了《关 于四川泸州步长生物制药有限公司与GOODFELLOW就注射用Efparepoetinalfa签署的议案》《关于拟转 让控股子公司股权及放弃优先受让权的议案》《关于控股子公司注册地址及名称变更的议案》。 （编辑 任世碧） ...

（文章来源：每日经济新闻） 2024年1至12月份，步长制药的营业收入构成为：医药行业占比99.71%，其他业务占比0.29%。 步长制药（SH 603858，收盘价：18.03元）8月7日晚间发布公告称，公司第五届第二十八次董事会会议 于2025年8月7日以通讯方式召开。会议审议了《关于四川泸州步长生物制药有限公司与GOODFELLOW 就注射用Efparepoetinalfa签署的议案》等文件。 ...